Global Vector-Based RNAi Market Growth 2020-2025
COVID-19, the disease it causes, surfaced in late 2019, and now had become a full-blown crisis worldwide. Over fifty key countries had declared a national emergency to combat coronavirus. With cases spreading, and the epicentre of the outbreak shifting to Europe, North America, India and Latin America, life in these regions has been upended the way it had been in Asia earlier in the developing crisis. As the coronavirus pandemic has worsened, the entertainment industry has been upended along with most every other facet of life. As experts work toward a better understanding, the world shudders in fear of the unknown, a worry that has rocked global financial markets, leading to daily volatility in the U.S. stock markets.
According to this latest study, the 2020 growth of Vector-Based RNAi will have significant change from previous year. By the most conservative estimates of global Vector-Based RNAi market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ xx million in 2019. We give this scenario a XX% probability, where under the scenario the supply chain will start to recover and quarantines and travel bans will ease, over the Q2. Longer-term, the effect of COVID-19 will be felt throughout the year with some degree of harm done by the virus. Over the next five years the Vector-Based RNAi market will register a XX% CAGR in terms of revenue, the global market size will reach US$ XX million by 2025.
This report presents a comprehensive overview, market shares, and growth opportunities of Vector-Based RNAi market by product type, application, key manufacturers and key regions and countries.
This study specially analyses the impact of Covid-19 outbreak on the Vector-Based RNAi, covering the supply chain analysis, impact assessment to the Vector-Based RNAi market size growth rate in several scenarios, and the measures to be undertaken by Vector-Based RNAi companies in response to the COVID-19 epidemic.
Segmentation by type: breakdown data from 2015 to 2020, in Section 2.3; and forecast to 2025 in section 11.7.
siRNA Design
siRNA Vectors
Custom siRNA Construction
Segmentation by application: breakdown data from 2015 to 2020, in Section 2.4; and forecast to 2024 in section 11.8.
Hospitals
Speciality Clinics
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Merck & Co.
Arcturus Therapeutics
Phio Pharmaceutical
Thermo Fisher Scientific
Silence Therapeutics
Quark Pharmaceuticals
Dicerna Pharmaceuticals
Qiagen NV
Arrowhead Pharmaceuticals
Ionis Pharmaceutical
Alnylam Pharmaceuticals
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Vector-Based RNAi consumption (value & volume) by key regions/countries, type and application, history data from 2015 to 2019, and forecast to 2025.
To understand the structure of Vector-Based RNAi market by identifying its various subsegments.
Focuses on the key global Vector-Based RNAi manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Vector-Based RNAi with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Vector-Based RNAi submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
Frequently Asked Questions
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
- By Type
- By Application
- By Region
- By Country
- By Manufacturer
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 What is the Impact of Covid-19 Outbreak On the Vector-Based RNAi?
1.8.1 Optimistic Scenario: COVID-19 Is Contained by May or June, with Normalcy Returning to Global Operations Through the End of Q2.
1.8.2 Conservative Scenario: COVID-19 Remains Prevalent, with Continued Impacts Lasting Into Q4.
1.8.3 Estimated Impact of the Coronavirus (COVID-19) Epidemic on the Global Vector-Based RNAi Market Size in 2020, by Scenario
1.8.4 Corporate Strategy the Manufacturers Should Be Thinking About Right Now
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Vector-Based RNAi Consumption 2015-2025
2.1.2 Vector-Based RNAi Consumption CAGR by Region
2.2 Vector-Based RNAi Segment by Type
2.2.1 siRNA Design
2.2.2 siRNA Vectors
2.2.3 Custom siRNA Construction
2.3 Vector-Based RNAi Consumption by Type
2.3.1 Global Vector-Based RNAi Consumption Market Share by Type (2015-2020)
2.3.2 Global Vector-Based RNAi Revenue and Market Share by Type (2015-2020)
2.3.3 Global Vector-Based RNAi Sale Price by Type (2015-2020)
2.4 Vector-Based RNAi Segment by Application
2.4.1 Hospitals
2.4.2 Speciality Clinics
2.5 Vector-Based RNAi Consumption by Application
2.5.1 Global Vector-Based RNAi Consumption Market Share by Type (2015-2020)
2.5.2 Global Vector-Based RNAi Value and Market Share by Type (2015-2020)
2.5.3 Global Vector-Based RNAi Sale Price by Type (2015-2020)
3 Global Vector-Based RNAi by Company
3.1 Global Vector-Based RNAi Sales Market Share by Company
3.1.1 Global Vector-Based RNAi Sales by Company (2018-2020)
3.1.2 Global Vector-Based RNAi Sales Market Share by Company (2018-2020)
3.2 Global Vector-Based RNAi Revenue Market Share by Company
3.2.1 Global Vector-Based RNAi Revenue by Company (2018-2020)
3.2.2 Global Vector-Based RNAi Revenue Market Share by Company (2018-2020)
3.3 Global Vector-Based RNAi Sale Price by Company
3.4 Global Vector-Based RNAi Manufacturing Base Distribution, Sales Area, Type by Company
3.4.1 Global Vector-Based RNAi Manufacturing Base Distribution and Sales Area by Company
3.4.2 Players Vector-Based RNAi Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2018-2020)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 Vector-Based RNAi by Regions
4.1 Vector-Based RNAi by Regions
4.2 Americas Vector-Based RNAi Consumption Growth
4.3 APAC Vector-Based RNAi Consumption Growth
4.4 Europe Vector-Based RNAi Consumption Growth
4.5 Middle East & Africa Vector-Based RNAi Consumption Growth
5 Americas
5.1 Americas Vector-Based RNAi Consumption by Countries
5.1.1 Americas Vector-Based RNAi Consumption by Countries (2015-2020)
5.1.2 Americas Vector-Based RNAi Value by Countries (2015-2020)
5.2 Americas Vector-Based RNAi Consumption by Type
5.3 Americas Vector-Based RNAi Consumption by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
5.8 Key Economic Indicators of Few Americas Countries
6 APAC
6.1 APAC Vector-Based RNAi Consumption by Regions
6.1.1 APAC Vector-Based RNAi Consumption by Regions (2015-2020)
6.1.2 APAC Vector-Based RNAi Value by Regions (2015-2020)
6.2 APAC Vector-Based RNAi Consumption by Type
6.3 APAC Vector-Based RNAi Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Regions
7 Europe
7.1 Europe Vector-Based RNAi by Countries
7.1.1 Europe Vector-Based RNAi Consumption by Countries (2015-2020)
7.1.2 Europe Vector-Based RNAi Value by Countries (2015-2020)
7.2 Europe Vector-Based RNAi Consumption by Type
7.3 Europe Vector-Based RNAi Consumption by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Key Economic Indicators of Few Europe Countries
8 Middle East & Africa
8.1 Middle East & Africa Vector-Based RNAi by Countries
8.1.1 Middle East & Africa Vector-Based RNAi Consumption by Countries (2015-2020)
8.1.2 Middle East & Africa Vector-Based RNAi Value by Countries (2015-2020)
8.2 Middle East & Africa Vector-Based RNAi Consumption by Type
8.3 Middle East & Africa Vector-Based RNAi Consumption by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends
10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Channels
10.1.2 Indirect Channels
10.2 Vector-Based RNAi Distributors
10.3 Vector-Based RNAi Customer
11 Global Vector-Based RNAi Market Forecast
11.1 Global Vector-Based RNAi Consumption Forecast (2021-2025)
11.2 Global Vector-Based RNAi Forecast by Regions
11.2.1 Global Vector-Based RNAi Forecast by Regions (2021-2025)
11.2.2 Global Vector-Based RNAi Value Forecast by Regions (2021-2025)
11.2.3 Americas Consumption Forecast
11.2.4 APAC Consumption Forecast
11.2.5 Europe Consumption Forecast
11.2.6 Middle East & Africa Consumption Forecast
11.3 Americas Forecast by Countries
11.3.1 United States Market Forecast
11.3.2 Canada Market Forecast
11.3.3 Mexico Market Forecast
11.3.4 Brazil Market Forecast
11.4 APAC Forecast by Countries
11.4.1 China Market Forecast
11.4.2 Japan Market Forecast
11.4.3 Korea Market Forecast
11.4.4 Southeast Asia Market Forecast
11.4.5 India Market Forecast
11.4.6 Australia Market Forecast
11.5 Europe Forecast by Countries
11.5.1 Germany Market Forecast
11.5.2 France Market Forecast
11.5.3 UK Market Forecast
11.5.4 Italy Market Forecast
11.5.5 Russia Market Forecast
11.6 Middle East & Africa Forecast by Countries
11.6.1 Egypt Market Forecast
11.6.2 South Africa Market Forecast
11.6.3 Israel Market Forecast
11.6.4 Turkey Market Forecast
11.6.5 GCC Countries Market Forecast
11.7 Global Vector-Based RNAi Forecast by Type
11.8 Global Vector-Based RNAi Forecast by Application
12 Key Players Analysis
12.1 Merck & Co.
12.1.1 Company Information
12.1.2 Vector-Based RNAi Product Offered
12.1.3 Merck & Co. Vector-Based RNAi Sales, Revenue, Price and Gross Margin (2018-2020)
12.1.4 Main Business Overview
12.1.5 Merck & Co. Latest Developments
12.2 Arcturus Therapeutics
12.2.1 Company Information
12.2.2 Vector-Based RNAi Product Offered
12.2.3 Arcturus Therapeutics Vector-Based RNAi Sales, Revenue, Price and Gross Margin (2018-2020)
12.2.4 Main Business Overview
12.2.5 Arcturus Therapeutics Latest Developments
12.3 Phio Pharmaceutical
12.3.1 Company Information
12.3.2 Vector-Based RNAi Product Offered
12.3.3 Phio Pharmaceutical Vector-Based RNAi Sales, Revenue, Price and Gross Margin (2018-2020)
12.3.4 Main Business Overview
12.3.5 Phio Pharmaceutical Latest Developments
12.4 Thermo Fisher Scientific
12.4.1 Company Information
12.4.2 Vector-Based RNAi Product Offered
12.4.3 Thermo Fisher Scientific Vector-Based RNAi Sales, Revenue, Price and Gross Margin (2018-2020)
12.4.4 Main Business Overview
12.4.5 Thermo Fisher Scientific Latest Developments
12.5 Silence Therapeutics
12.5.1 Company Information
12.5.2 Vector-Based RNAi Product Offered
12.5.3 Silence Therapeutics Vector-Based RNAi Sales, Revenue, Price and Gross Margin (2018-2020)
12.5.4 Main Business Overview
12.5.5 Silence Therapeutics Latest Developments
12.6 Quark Pharmaceuticals
12.6.1 Company Information
12.6.2 Vector-Based RNAi Product Offered
12.6.3 Quark Pharmaceuticals Vector-Based RNAi Sales, Revenue, Price and Gross Margin (2018-2020)
12.6.4 Main Business Overview
12.6.5 Quark Pharmaceuticals Latest Developments
12.7 Dicerna Pharmaceuticals
12.7.1 Company Information
12.7.2 Vector-Based RNAi Product Offered
12.7.3 Dicerna Pharmaceuticals Vector-Based RNAi Sales, Revenue, Price and Gross Margin (2018-2020)
12.7.4 Main Business Overview
12.7.5 Dicerna Pharmaceuticals Latest Developments
12.8 Qiagen NV
12.8.1 Company Information
12.8.2 Vector-Based RNAi Product Offered
12.8.3 Qiagen NV Vector-Based RNAi Sales, Revenue, Price and Gross Margin (2018-2020)
12.8.4 Main Business Overview
12.8.5 Qiagen NV Latest Developments
12.9 Arrowhead Pharmaceuticals
12.9.1 Company Information
12.9.2 Vector-Based RNAi Product Offered
12.9.3 Arrowhead Pharmaceuticals Vector-Based RNAi Sales, Revenue, Price and Gross Margin (2018-2020)
12.9.4 Main Business Overview
12.9.5 Arrowhead Pharmaceuticals Latest Developments
12.10 Ionis Pharmaceutical
12.10.1 Company Information
12.10.2 Vector-Based RNAi Product Offered
12.10.3 Ionis Pharmaceutical Vector-Based RNAi Sales, Revenue, Price and Gross Margin (2018-2020)
12.10.4 Main Business Overview
12.10.5 Ionis Pharmaceutical Latest Developments
12.11 Alnylam Pharmaceuticals
12.11.1 Company Information
12.11.2 Vector-Based RNAi Product Offered
12.11.3 Alnylam Pharmaceuticals Vector-Based RNAi Sales, Revenue, Price and Gross Margin (2018-2020)
12.11.4 Main Business Overview
12.11.5 Alnylam Pharmaceuticals Latest Developments
13 Research Findings and Conclusion
List of Tables
Table 1. Estimated Impact of the Coronavirus (COVID-19) Epidemic on the Global Vector-Based RNAi Market Size in 2020, by Scenario
Table 2. COVID-19: Measures to be Undertaken by Vector-Based RNAi Companies
Table 3. Research Methodology
Table 4. Data Source
Table 5. Vector-Based RNAi Consumption CAGR by Region 2015-2025 ($ Millions)
Table 6. Major Players of siRNA Design
Table 7. Major Players of siRNA Vectors
Table 8. Major Players of Custom siRNA Construction
Table 9. Global Consumption Sales by Type (2015-2020)
Table 10. Global Vector-Based RNAi Consumption Market Share by Type (2015-2020)
Table 11. Global Vector-Based RNAi Revenue by Type (2015-2020) ($ million)
Table 12. Global Vector-Based RNAi Value Market Share by Type (2015-2020) ($ Millions)
Table 13. Global Vector-Based RNAi Sale Price by Type (2015-2020)
Table 14. Global Consumption Sales by Application (2015-2020)
Table 15. Global Vector-Based RNAi Consumption Market Share by Application (2015-2020)
Table 16. Global Vector-Based RNAi Value by Application (2015-2020)
Table 17. Global Vector-Based RNAi Value Market Share by Application (2015-2020)
Table 18. Global Vector-Based RNAi Sale Price by Application (2015-2020)
Table 19. Global Vector-Based RNAi Sales by Company (2017-2019) (K Units)
Table 20. Global Vector-Based RNAi Sales Market Share by Company (2017-2019)
Table 21. Global Vector-Based RNAi Revenue by Company (2017-2019) ($ Millions)
Table 22. Global Vector-Based RNAi Revenue Market Share by Company (2017-2019)
Table 23. Global Vector-Based RNAi Sale Price by Company (2017-2019)
Table 24. Global Vector-Based RNAi Manufacturing Base Distribution and Sales Area by Manufacturers
Table 25. Players Vector-Based RNAi Products Offered
Table 26. Vector-Based RNAi Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
Table 27. Global Vector-Based RNAi Consumption by Regions 2015-2020 (K Units)
Table 28. Global Vector-Based RNAi Consumption Market Share by Regions 2015-2020
Table 29. Global Vector-Based RNAi Value by Regions 2015-2020 ($ Millions)
Table 30. Global Vector-Based RNAi Value Market Share by Regions 2015-2020
Table 31. Americas Vector-Based RNAi Consumption by Countries (2015-2020) (K Units)
Table 32. Americas Vector-Based RNAi Consumption Market Share by Countries (2015-2020)
Table 33. Americas Vector-Based RNAi Value by Countries (2015-2020) ($ Millions)
Table 34. Americas Vector-Based RNAi Value Market Share by Countries (2015-2020)
Table 35. Americas Vector-Based RNAi Consumption by Type (2015-2020) (K Units)
Table 36. Americas Vector-Based RNAi Consumption Market Share by Type (2015-2020)
Table 37. Americas Vector-Based RNAi Consumption by Application (2015-2020) (K Units)
Table 38. Americas Vector-Based RNAi Consumption Market Share by Application (2015-2020)
Table 39. APAC Vector-Based RNAi Consumption by Countries (2015-2020) (K Units)
Table 40. APAC Vector-Based RNAi Consumption Market Share by Countries (2015-2020)
Table 41. APAC Vector-Based RNAi Value by Regions (2015-2020) ($ Millions)
Table 42. APAC Vector-Based RNAi Value Market Share by Regions (2015-2020)
Table 43. APAC Vector-Based RNAi Consumption by Type (2015-2020) (K Units)
Table 44. APAC Vector-Based RNAi Consumption Market Share by Type (2015-2020)
Table 45. APAC Vector-Based RNAi Consumption by Application (2015-2020) (K Units)
Table 46. APAC Vector-Based RNAi Consumption Market Share by Application (2015-2020)
Table 47. Europe Vector-Based RNAi Consumption by Countries (2015-2020) (K Units)
Table 48. Europe Vector-Based RNAi Consumption Market Share by Countries (2015-2020)
Table 49. Europe Vector-Based RNAi Value by Countries (2015-2020) ($ Millions)
Table 50. Europe Vector-Based RNAi Value Market Share by Countries (2015-2020)
Table 51. Europe Vector-Based RNAi Consumption by Type (2015-2020) (K Units)
Table 52. Europe Vector-Based RNAi Consumption Market Share by Type (2015-2020)
Table 53. Europe Vector-Based RNAi Consumption by Application (2015-2020) (K Units)
Table 54. Europe Vector-Based RNAi Consumption Market Share by Application (2015-2020)
Table 55. Middle East & Africa Vector-Based RNAi Consumption by Countries (2015-2020) (K Units)
Table 56. Middle East & Africa Vector-Based RNAi Consumption Market Share by Countries (2015-2020)
Table 57. Middle East & Africa Vector-Based RNAi Value by Countries (2015-2020) ($ Millions)
Table 58. Middle East & Africa Vector-Based RNAi Value Market Share by Countries (2015-2020)
Table 59. Middle East & Africa Vector-Based RNAi Consumption by Type (2015-2020) (K Units)
Table 60. Middle East & Africa Vector-Based RNAi Consumption Market Share by Type (2015-2020)
Table 61. Middle East & Africa Vector-Based RNAi Consumption by Application (2015-2020) (K Units)
Table 62. Middle East & Africa Vector-Based RNAi Consumption Market Share by Application (2015-2020)
Table 63. Vector-Based RNAi Distributors List
Table 64. Vector-Based RNAi Customer List
Table 65. Global Vector-Based RNAi Consumption Forecast by Countries (2021-2025) (K Units)
Table 66. Global Vector-Based RNAi Consumption Market Forecast by Regions
Table 67. Global Vector-Based RNAi Value Forecast by Countries (2021-2025) ($ Millions)
Table 68. Global Vector-Based RNAi Value Market Share Forecast by Regions
Table 69. Global Vector-Based RNAi Consumption Forecast by Type (2021-2025) (K Units)
Table 70. Global Vector-Based RNAi Consumption Market Share Forecast by Type (2021-2025)
Table 71. Global Vector-Based RNAi Value Forecast by Type (2021-2025) ($ Millions)
Table 72. Global Vector-Based RNAi Value Market Share Forecast by Type (2021-2025)
Table 73. Global Vector-Based RNAi Consumption Forecast by Application (2021-2025) (K Units)
Table 74. Global Vector-Based RNAi Consumption Market Share Forecast by Application (2021-2025)
Table 75. Global Vector-Based RNAi Value Forecast by Application (2021-2025) ($ Millions)
Table 76. Global Vector-Based RNAi Value Market Share Forecast by Application (2021-2025)
Table 77. Merck & Co. Product Offered
Table 78. Merck & Co. Vector-Based RNAi Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 79. Merck & Co. Main Business
Table 80. Merck & Co. Latest Developments
Table 81. Merck & Co. Basic Information, Company Total Revenue (in $ million), Vector-Based RNAi Manufacturing Base, Sales Area and Its Competitors
Table 82. Arcturus Therapeutics Product Offered
Table 83. Arcturus Therapeutics Vector-Based RNAi Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 84. Arcturus Therapeutics Main Business
Table 85. Arcturus Therapeutics Latest Developments
Table 86. Arcturus Therapeutics Basic Information, Company Total Revenue (in $ million), Vector-Based RNAi Manufacturing Base, Sales Area and Its Competitors
Table 87. Phio Pharmaceutical Product Offered
Table 88. Phio Pharmaceutical Vector-Based RNAi Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 89. Phio Pharmaceutical Main Business
Table 90. Phio Pharmaceutical Latest Developments
Table 91. Phio Pharmaceutical Basic Information, Company Total Revenue (in $ million), Vector-Based RNAi Manufacturing Base, Sales Area and Its Competitors
Table 92. Thermo Fisher Scientific Product Offered
Table 93. Thermo Fisher Scientific Vector-Based RNAi Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 94. Thermo Fisher Scientific Main Business
Table 95. Thermo Fisher Scientific Latest Developments
Table 96. Thermo Fisher Scientific Basic Information, Company Total Revenue (in $ million), Vector-Based RNAi Manufacturing Base, Sales Area and Its Competitors
Table 97. Silence Therapeutics Product Offered
Table 98. Silence Therapeutics Vector-Based RNAi Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 99. Silence Therapeutics Main Business
Table 100. Silence Therapeutics Latest Developments
Table 101. Silence Therapeutics Basic Information, Company Total Revenue (in $ million), Vector-Based RNAi Manufacturing Base, Sales Area and Its Competitors
Table 102. Quark Pharmaceuticals Product Offered
Table 103. Quark Pharmaceuticals Vector-Based RNAi Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 104. Quark Pharmaceuticals Main Business
Table 105. Quark Pharmaceuticals Latest Developments
Table 106. Quark Pharmaceuticals Basic Information, Company Total Revenue (in $ million), Vector-Based RNAi Manufacturing Base, Sales Area and Its Competitors
Table 107. Dicerna Pharmaceuticals Product Offered
Table 108. Dicerna Pharmaceuticals Basic Information, Company Total Revenue (in $ million), Vector-Based RNAi Manufacturing Base, Sales Area and Its Competitors
Table 109. Dicerna Pharmaceuticals Main Business
Table 110. Dicerna Pharmaceuticals Latest Developments
Table 111. Dicerna Pharmaceuticals Vector-Based RNAi Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 112. Qiagen NV Product Offered
Table 113. Qiagen NV Vector-Based RNAi Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 114. Qiagen NV Main Business
Table 115. Qiagen NV Latest Developments
Table 116. Qiagen NV Basic Information, Company Total Revenue (in $ million), Vector-Based RNAi Manufacturing Base, Sales Area and Its Competitors
Table 117. Arrowhead Pharmaceuticals Product Offered
Table 118. Arrowhead Pharmaceuticals Vector-Based RNAi Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 119. Arrowhead Pharmaceuticals Main Business
Table 120. Arrowhead Pharmaceuticals Latest Developments
Table 121. Arrowhead Pharmaceuticals Basic Information, Company Total Revenue (in $ million), Vector-Based RNAi Manufacturing Base, Sales Area and Its Competitors
Table 122. Ionis Pharmaceutical Product Offered
Table 123. Ionis Pharmaceutical Vector-Based RNAi Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 124. Ionis Pharmaceutical Main Business
Table 125. Ionis Pharmaceutical Latest Developments
Table 126. Ionis Pharmaceutical Basic Information, Company Total Revenue (in $ million), Vector-Based RNAi Manufacturing Base, Sales Area and Its Competitors
Table 127. Alnylam Pharmaceuticals Product Offered
Table 128. Alnylam Pharmaceuticals Vector-Based RNAi Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 129. Alnylam Pharmaceuticals Main Business
Table 130. Alnylam Pharmaceuticals Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table 131. Alnylam Pharmaceuticals Latest Developments
List of Figures
Figure 1. Picture of Vector-Based RNAi
Figure 2. Vector-Based RNAi Report Years Considered
Figure 3. Market Research Methodology
Figure 4. Global Vector-Based RNAi Consumption Growth Rate 2015-2025 (K Units)
Figure 5. Global Vector-Based RNAi Value Growth Rate 2015-2025 ($ Millions)
Figure 6. Product Picture of siRNA Design
Figure 7. Product Picture of siRNA Vectors
Figure 8. Product Picture of Custom siRNA Construction
Figure 9. Global Vector-Based RNAi Consumption Market Share by Type (2015-2020)
Figure 10. Global Vector-Based RNAi Value Market Share by Type (2015-2020)
Figure 11. Vector-Based RNAi Consumed in Hospitals
Figure 12. Global Vector-Based RNAi Market: Hospitals (2015-2020) (K Units)
Figure 13. Global Vector-Based RNAi Market: Hospitals (2015-2020) ($ Millions)
Figure 14. Vector-Based RNAi Consumed in Speciality Clinics
Figure 15. Global Vector-Based RNAi Market: Speciality Clinics (2015-2020) (K Units)
Figure 16. Global Vector-Based RNAi Market: Speciality Clinics (2015-2020) ($ Millions)
Figure 17. Global Vector-Based RNAi Consumption Market Share by Application (2015-2020)
Figure 18. Global Vector-Based RNAi Value Market Share by Application (2015-2020)
Figure 19. Global Vector-Based RNAi Sales Market Share by Company in 2017
Figure 20. Global Vector-Based RNAi Sales Market Share by Company in 2019
Figure 21. Global Vector-Based RNAi Revenue Market Share by Company in 2017
Figure 22. Global Vector-Based RNAi Revenue Market Share by Company in 2019
Figure 23. Global Vector-Based RNAi Sale Price by Company in 2019
Figure 24. Global Vector-Based RNAi Consumption Market Share by Regions 2015-2020
Figure 25. Global Vector-Based RNAi Value Market Share by Regions 2015-2020
Figure 26. Americas Vector-Based RNAi Consumption 2015-2020 (K Units)
Figure 27. Americas Vector-Based RNAi Value 2015-2020 ($ Millions)
Figure 28. APAC Vector-Based RNAi Consumption 2015-2020 (K Units)
Figure 29. APAC Vector-Based RNAi Value 2015-2020 ($ Millions)
Figure 30. Europe Vector-Based RNAi Consumption 2015-2020 (K Units)
Figure 31. Europe Vector-Based RNAi Value 2015-2020 ($ Millions)
Figure 32. Middle East & Africa Vector-Based RNAi Consumption 2015-2020 (K Units)
Figure 33. Middle East & Africa Vector-Based RNAi Value 2015-2020 ($ Millions)
Figure 34. Americas Vector-Based RNAi Consumption Market Share by Countries in 2019
Figure 35. Americas Vector-Based RNAi Value Market Share by Countries in 2019
Figure 36. Americas Vector-Based RNAi Consumption Market Share by Type in 2019
Figure 37. Americas Vector-Based RNAi Consumption Market Share by Application in 2019
Figure 38. United States Vector-Based RNAi Consumption Growth 2015-2020 (K Units)
Figure 39. United States Vector-Based RNAi Value Growth 2015-2020 ($ Millions)
Figure 40. Canada Vector-Based RNAi Consumption Growth 2015-2020 (K Units)
Figure 41. Canada Vector-Based RNAi Value Growth 2015-2020 ($ Millions)
Figure 42. Mexico Vector-Based RNAi Consumption Growth 2015-2020 (K Units)
Figure 43. Mexico Vector-Based RNAi Value Growth 2015-2020 ($ Millions)
Figure 44. APAC Vector-Based RNAi Consumption Market Share by Countries in 2019
Figure 45. APAC Vector-Based RNAi Value Market Share by Regions in 2019
Figure 46. APAC Vector-Based RNAi Consumption Market Share by Type in 2019
Figure 47. APAC Vector-Based RNAi Consumption Market Share by Application in 2019
Figure 48. China Vector-Based RNAi Consumption Growth 2015-2020 (K Units)
Figure 49. China Vector-Based RNAi Value Growth 2015-2020 ($ Millions)
Figure 50. Japan Vector-Based RNAi Consumption Growth 2015-2020 (K Units)
Figure 51. Japan Vector-Based RNAi Value Growth 2015-2020 ($ Millions)
Figure 52. Korea Vector-Based RNAi Consumption Growth 2015-2020 (K Units)
Figure 53. Korea Vector-Based RNAi Value Growth 2015-2020 ($ Millions)
Figure 54. Southeast Asia Vector-Based RNAi Consumption Growth 2015-2020 (K Units)
Figure 55. Southeast Asia Vector-Based RNAi Value Growth 2015-2020 ($ Millions)
Figure 56. India Vector-Based RNAi Consumption Growth 2015-2020 (K Units)
Figure 57. India Vector-Based RNAi Value Growth 2015-2020 ($ Millions)
Figure 58. Australia Vector-Based RNAi Consumption Growth 2015-2020 (K Units)
Figure 59. Australia Vector-Based RNAi Value Growth 2015-2020 ($ Millions)
Figure 60. Europe Vector-Based RNAi Consumption Market Share by Countries in 2019
Figure 61. Europe Vector-Based RNAi Value Market Share by Countries in 2019
Figure 62. Europe Vector-Based RNAi Consumption Market Share by Type in 2019
Figure 63. Europe Vector-Based RNAi Consumption Market Share by Application in 2019
Figure 64. Germany Vector-Based RNAi Consumption Growth 2015-2020 (K Units)
Figure 65. Germany Vector-Based RNAi Value Growth 2015-2020 ($ Millions)
Figure 66. France Vector-Based RNAi Consumption Growth 2015-2020 (K Units)
Figure 67. France Vector-Based RNAi Value Growth 2015-2020 ($ Millions)
Figure 68. UK Vector-Based RNAi Consumption Growth 2015-2020 (K Units)
Figure 69. UK Vector-Based RNAi Value Growth 2015-2020 ($ Millions)
Figure 70. Italy Vector-Based RNAi Consumption Growth 2015-2020 (K Units)
Figure 71. Italy Vector-Based RNAi Value Growth 2015-2020 ($ Millions)
Figure 72. Russia Vector-Based RNAi Consumption Growth 2015-2020 (K Units)
Figure 73. Russia Vector-Based RNAi Value Growth 2015-2020 ($ Millions)
Figure 74. Middle East & Africa Vector-Based RNAi Consumption Market Share by Countries in 2019
Figure 75. Middle East & Africa Vector-Based RNAi Value Market Share by Countries in 2019
Figure 76. Middle East & Africa Vector-Based RNAi Consumption Market Share by Type in 2019
Figure 77. Middle East & Africa Vector-Based RNAi Consumption Market Share by Application in 2019
Figure 78. Egypt Vector-Based RNAi Consumption Growth 2015-2020 (K Units)
Figure 79. Egypt Vector-Based RNAi Value Growth 2015-2020 ($ Millions)
Figure 80. South Africa Vector-Based RNAi Consumption Growth 2015-2020 (K Units)
Figure 81. South Africa Vector-Based RNAi Value Growth 2015-2020 ($ Millions)
Figure 82. Israel Vector-Based RNAi Consumption Growth 2015-2020 (K Units)
Figure 83. Israel Vector-Based RNAi Value Growth 2015-2020 ($ Millions)
Figure 84. Turkey Vector-Based RNAi Consumption Growth 2015-2020 (K Units)
Figure 85. Turkey Vector-Based RNAi Value Growth 2015-2020 ($ Millions)
Figure 86. GCC Countries Vector-Based RNAi Consumption Growth 2015-2020 (K Units)
Figure 87. GCC Countries Vector-Based RNAi Value Growth 2015-2020 ($ Millions)
Figure 88. Global Vector-Based RNAi Consumption Growth Rate Forecast (2021-2025) (K Units)
Figure 89. Global Vector-Based RNAi Value Growth Rate Forecast (2021-2025) ($ Millions)
Figure 90. Americas Vector-Based RNAi Consumption 2021-2025 (K Units)
Figure 91. Americas Vector-Based RNAi Value 2021-2025 ($ Millions)
Figure 92. APAC Vector-Based RNAi Consumption 2021-2025 (K Units)
Figure 93. APAC Vector-Based RNAi Value 2021-2025 ($ Millions)
Figure 94. Europe Vector-Based RNAi Consumption 2021-2025 (K Units)
Figure 95. Europe Vector-Based RNAi Value 2021-2025 ($ Millions)
Figure 96. Middle East & Africa Vector-Based RNAi Consumption 2021-2025 (K Units)
Figure 97. Middle East & Africa Vector-Based RNAi Value 2021-2025 ($ Millions)
Figure 98. United States Vector-Based RNAi Consumption 2021-2025 (K Units)
Figure 99. United States Vector-Based RNAi Value 2021-2025 ($ Millions)
Figure 100. Canada Vector-Based RNAi Consumption 2021-2025 (K Units)
Figure 101. Canada Vector-Based RNAi Value 2021-2025 ($ Millions)
Figure 102. Mexico Vector-Based RNAi Consumption 2021-2025 (K Units)
Figure 103. Mexico Vector-Based RNAi Value 2021-2025 ($ Millions)
Figure 104. Brazil Vector-Based RNAi Consumption 2021-2025 (K Units)
Figure 105. Brazil Vector-Based RNAi Value 2021-2025 ($ Millions)
Figure 106. China Vector-Based RNAi Consumption 2021-2025 (K Units)
Figure 107. China Vector-Based RNAi Value 2021-2025 ($ Millions)
Figure 108. Japan Vector-Based RNAi Consumption 2021-2025 (K Units)
Figure 109. Japan Vector-Based RNAi Value 2021-2025 ($ Millions)
Figure 110. Korea Vector-Based RNAi Consumption 2021-2025 (K Units)
Figure 111. Korea Vector-Based RNAi Value 2021-2025 ($ Millions)
Figure 112. Southeast Asia Vector-Based RNAi Consumption 2021-2025 (K Units)
Figure 113. Southeast Asia Vector-Based RNAi Value 2021-2025 ($ Millions)
Figure 114. India Vector-Based RNAi Consumption 2021-2025 (K Units)
Figure 115. India Vector-Based RNAi Value 2021-2025 ($ Millions)
Figure 116. Australia Vector-Based RNAi Consumption 2021-2025 (K Units)
Figure 117. Australia Vector-Based RNAi Value 2021-2025 ($ Millions)
Figure 118. Germany Vector-Based RNAi Consumption 2021-2025 (K Units)
Figure 119. Germany Vector-Based RNAi Value 2021-2025 ($ Millions)
Figure 120. France Vector-Based RNAi Consumption 2021-2025 (K Units)
Figure 121. France Vector-Based RNAi Value 2021-2025 ($ Millions)
Figure 122. UK Vector-Based RNAi Consumption 2021-2025 (K Units)
Figure 123. UK Vector-Based RNAi Value 2021-2025 ($ Millions)
Figure 124. Italy Vector-Based RNAi Consumption 2021-2025 (K Units)
Figure 125. Italy Vector-Based RNAi Value 2021-2025 ($ Millions)
Figure 126. Russia Vector-Based RNAi Consumption 2021-2025 (K Units)
Figure 127. Russia Vector-Based RNAi Value 2021-2025 ($ Millions)
Figure 128. Spain Vector-Based RNAi Consumption 2021-2025 (K Units)
Figure 129. Spain Vector-Based RNAi Value 2021-2025 ($ Millions)
Figure 130. Egypt Vector-Based RNAi Consumption 2021-2025 (K Units)
Figure 131. Egypt Vector-Based RNAi Value 2021-2025 ($ Millions)
Figure 132. South Africa Vector-Based RNAi Consumption 2021-2025 (K Units)
Figure 133. South Africa Vector-Based RNAi Value 2021-2025 ($ Millions)
Figure 134. Israel Vector-Based RNAi Consumption 2021-2025 (K Units)
Figure 135. Israel Vector-Based RNAi Value 2021-2025 ($ Millions)
Figure 136. Turkey Vector-Based RNAi Consumption 2021-2025 (K Units)
Figure 137. Turkey Vector-Based RNAi Value 2021-2025 ($ Millions)
Figure 138. GCC Countries Vector-Based RNAi Consumption 2021-2025 (K Units)
Figure 139. GCC Countries Vector-Based RNAi Value 2021-2025 ($ Millions)
Figure 140. Merck & Co. Vector-Based RNAi Market Share (2018-2020)
Figure 141. Arcturus Therapeutics Vector-Based RNAi Market Share (2018-2020)
Figure 142. Phio Pharmaceutical Vector-Based RNAi Market Share (2018-2020)
Figure 143. Thermo Fisher Scientific Vector-Based RNAi Market Share (2018-2020)
Figure 144. Silence Therapeutics Vector-Based RNAi Market Share (2018-2020)
Figure 145. Quark Pharmaceuticals Vector-Based RNAi Market Share (2018-2020)
Figure 146. Dicerna Pharmaceuticals Vector-Based RNAi Market Share (2018-2020)
Figure 147. Qiagen NV Vector-Based RNAi Market Share (2018-2020)
Figure 148. Arrowhead Pharmaceuticals Vector-Based RNAi Market Share (2018-2020)
Figure 149. Ionis Pharmaceutical Vector-Based RNAi Market Share (2018-2020)
Figure 150. Alnylam Pharmaceuticals Vector-Based RNAi Market Share (2018-2020)
